KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Intangibles (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 16 years of Intangibles data on record, last reported at $831.6 million in Q3 2024.

  • For Q3 2024, Intangibles rose 37.77% year-over-year to $831.6 million; the TTM value through Sep 2024 reached $831.6 million, up 37.77%, while the annual FY2023 figure was $839.9 million, 39.15% up from the prior year.
  • Intangibles reached $831.6 million in Q3 2024 per VRTX's latest filing, down from $837.5 million in the prior quarter.
  • Across five years, Intangibles topped out at $839.9 million in Q4 2023 and bottomed at $387.0 million in Q2 2022.
  • Average Intangibles over 5 years is $544.7 million, with a median of $400.0 million recorded in 2020.
  • Peak YoY movement for Intangibles: dropped 3.25% in 2022, then skyrocketed 55.97% in 2023.
  • A 5-year view of Intangibles shows it stood at $400.0 million in 2020, then changed by 0.0% to $400.0 million in 2021, then surged by 50.9% to $603.6 million in 2022, then skyrocketed by 39.15% to $839.9 million in 2023, then fell by 0.99% to $831.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Intangibles were $831.6 million in Q3 2024, $837.5 million in Q2 2024, and $834.9 million in Q1 2024.